



## Arbutus to Report Third Quarter 2020 Financial Results and Provide Corporate Update

October 29, 2020

WARMINSTER, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its third quarter 2020 financial results and corporate update for Thursday, November 5, 2020. The schedule for the press release and conference call/webcast are as follows:

- Q3 2020 Press Release: November 5, 2020 at 7:30 a.m. ET
- Q3 2020 Conference Call/Webcast: November 5, 2020 at 8:45 a.m. ET
- Domestic Dial-In Number: (866) 393-1607
- International Dial-In Number: (914) 495-8556
- Conference ID Number: 7161816

A live webcast of the conference call can be accessed through the Investors section of Arbutus' website at [www.arbutusbio.com](http://www.arbutusbio.com) or directly at [Live Webcast](#).

An archived webcast will be available on the Arbutus website after the event. Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID: 7161816.

### About Arbutus

Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19). For more information, visit [www.arbutusbio.com](http://www.arbutusbio.com).

### Contact Information

#### **Investors and Media**

William H. Collier  
President and CEO  
Phone: 267-469-0914  
Email: [ir@arbutusbio.com](mailto:ir@arbutusbio.com)

Pam Murphy  
Investor Relations Consultant  
Phone: 267-469-0914  
Email: [ir@arbutusbio.com](mailto:ir@arbutusbio.com)